biostudies-literatureUnknown43(13)Banning APVolcano Corporation and Boston ScientificEuropean Cardiovascular Research InstituteNational Institue for Health Research Biomedical Research Centre, Oxford<h4>Aims</h4>The SYNTAX II study evaluated the impact of advances in percutaneous coronary intervention (PCI), integrated into a single revascularization strategy, on outcomes of patients with de novo three-vessel disease. The study employed decision-making utilizing the SYNTAX score II, use of coronary physiology, thin-strut biodegradable polymer drug-eluting stents, intravascular ultrasound, enhanced treatments of chronic total occlusions, and optimized medical therapy. Patients treated with this approach were compared with predefined patients from the SYNTAX I trial.<h4>Methods and results</h4>SYNTAX II was a multicentre, single-arm, open-label study of patients requiring revascularization who demonstrated clinical equipoise for treatment with either coronary artery bypass grafting (CABEuropean heart journal1307-1316https://www.ebi.ac.uk/biostudies/studies/S-EPMC8970987biostudies-literatureFive-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study.PMC8970987Ochala ARyan NOnuma YVan Mieghem NMFath-Ordoubadi FCruz-Gonzalez ISabate MHildick-Smith DTaggart DTijssen JHoole SPAppleby CJan van Geuns RUren NZueco JFarooq VPiek JJIniguez ASpitzer EWalsh SDudek DLesiak MBuszman PEscaned JZaman AMoreno RSerruys PDe Maria GLDavies JBanning APGonzalo Nde Vries TGoicolea JfalseFive-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study.<h4>Aims</h4>The SYNTAX II study evaluated the impact of advances in percutaneous coronary intervention (PCI), integrated into a single revascularization strategy, on outcomes of patients with de novo three-vessel disease. The study employed decision-making utilizing the SYNTAX score II, use of coronary physiology, thin-strut biodegradable polymer drug-eluting stents, intravascular ultrasound, enhanced treatments of chronic total occlusions, and optimized medical therapy. Patients treated with this approach were compared with predefined patients from the SYNTAX I trial.<h4>Methods and results</h4>SYNTAX II was a multicentre, single-arm, open-label study of patients requiring revascularization who demonstrated clinical equipoise for treatment with either coronary artery bypass grafting (CAB2022-01-01T00:00:00Z2022 Mar2025-04-05T00:27:34.156Z2024-10-18T03:20:29.454ZS-EPMC89709873461799310.1093/eurheartj/ehab703